BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory

  • VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The move provides BioNxt with enhanced R&D capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub.